Clinical Research Directory

A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis

Palmoplantar psoriasis (PPPsO) is a type of psoriasis that affects the palms of hands and soles of the feet. It can cause red, thick, scaly patches, and it is often associated with pain and itching. These symptoms can make daily life hard and can have a bigger effect on quality of life than psoriasis in some other areas of the body. Treatment can also be difficult because the skin on the palms and soles is thick, so treatments put on the skin (topical treatments) may not work as well. The main aim of this study is to find out how well zasocitinib works in reducing the skin redness, thickening, scaling, as well as fissures (narrow, elongated tears) on palms and soles of adults. Other aims are to learn if zasocitinib reduces the surface area of psoriasis on the palms and soles in adults with mainly Palmoplantar psoriasis. The study is conducted in 2 parts with a possibility of continued treatment (long-term extension). In Part 1, participants will receive zasocitinib for 4 months (16 weeks). Participants who finish Part 1 may be able to continue to Part 2 if the study doctor thinks they would benefit. Participants who continue to Part 2, will keep taking zasocitinib until they have been treated for about 1 year (52 weeks). After that, participants may choose to keep taking zasocitinib for another year (52 weeks). Participants will be followed for about 1 month (4 weeks) after the end of treatment. During the study, participants will visit their study clinic 16 times.

Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema

Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Because these conditions can look alike, distinguishing between them in routine clinical practice may be difficult. This prospective, single-center observational study was designed to compare polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in adult patients with palmoplantar psoriasis and palmoplantar eczema. A total of 81 patients aged 18 years and older were included: 41 patients with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis and 40 patients with palmoplantar eczema. Dermoscopic and UVFD images were evaluated to identify vascular, scaling, surface, and fluorescence-related features that may help differentiate palmoplantar psoriasis from palmoplantar eczema. The study aims to assess whether these non-invasive imaging methods can provide additional diagnostic clues to support clinical evaluation.

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.